Biotech Values

[DewDiligence]

Results of Solanezumab survey in #msg-80447414:

There were 16 votes cast.


Q1: Will LLY conduct new phase-3 studies for Solanezumab in mild AD?

Yes: 94%
No: 6%


Q2: Should LLY conduct new phase-3 studies for Solanezumab in mild AD?

Yes: 44%
No: 56%


Q3: All told, what is the probability that Solanezumab makes it to market and sells $1B+ in peak annual sales?

a) <5%: 44%
b) 5-24.9%: 19%
c) 25-49.9%: 25%
d) 50-74.9%: 13%
e) 75%+: 0%


Thanks to all of the participants for participating.